Fan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fan Yang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Binyu Zhang
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
22 shared publications - Guanyin Huang
Southern University of Science and Technology 1 Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine Shenzhen, China
22 shared publications - Hailiang Hu
Department of Biochemistry, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology, Shenzhen, China
22 shared publications - Hao Yu
Institute of Biomedical and Health Engineering, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
22 shared publications - Haoyuan Tan
Key University Laboratory of Metabolism and Health of Guangdong, Biochemistry Department, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China
22 shared publications - Hongchang Li
Shenzhen Institute of Advanced Technology 7 Guangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials Chinese Academy of Sciences, Shenzhen, China
22 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S6. Senescent features are diminished in established lung metastasis derived from CTTN KD-induced senescent CTCs
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S6. Senescent features are diminished in established lung metastasis derived from CTTN KD-induced senescent CTCs
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S17 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S17. The MEK inhibitor, cobimetinib, sensitizes senescent CTCs to apoptosis
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S17 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S17. The MEK inhibitor, cobimetinib, sensitizes senescent CTCs to apoptosis
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S7. Transcriptomic and proteomic changes of melanoma cells upon cortactin depletion
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S7. Transcriptomic and proteomic changes of melanoma cells upon cortactin depletion
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S3. Single-cell RNA-seq of early CTC cultures reveals heterogenous expression of CTTN in single CTCs that are inversely correlated with the senescence state
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S3. Single-cell RNA-seq of early CTC cultures reveals heterogenous expression of CTTN in single CTCs that are inversely correlated with the senescence state
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S4. Cortactin depletion inhibits melanoma tumorigenesis and metastasis
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S4. Cortactin depletion inhibits melanoma tumorigenesis and metastasis
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S8. CTTN KD-induced cellular senescence and growth suppression is p53-dependent
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S8. CTTN KD-induced cellular senescence and growth suppression is p53-dependent
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S13. Cortactin depletion results in mtROS elevation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S13. Cortactin depletion results in mtROS elevation
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S14. Cortactin KD induces time-course dependent p53 activation and mtROS elevation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S14. Cortactin KD induces time-course dependent p53 activation and mtROS elevation
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S2, antibody infomation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S2, antibody infomation
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S10. KD CTTN leads to aberrant Rab7-positive late endosomal aggregates with mTOR co-localization and activation
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary figure S10. KD CTTN leads to aberrant Rab7-positive late endosomal aggregates with mTOR co-localization and activation